BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 37432545)

  • 21. Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama.
    Marchetti P; Di Rocco CZ; Ricevuto E; Bisegna R; Cianci G; Calista F; Sidoni T; Porzio G; Ficorella C
    Ann Oncol; 2004; 15 Suppl 1():I27-I34. PubMed ID: 15280184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
    Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
    Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selected medical interventions in women with a deleterious
    Hanley GE; McAlpine JN; Cheifetz R; Schrader KA; McCullum M; Huntsman D
    Curr Oncol; 2019 Feb; 26(1):e17-e23. PubMed ID: 30853805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer.
    Anderson C; Nichols HB; House M; Sandler DP
    Cancer Prev Res (Phila); 2019 Nov; 12(11):801-808. PubMed ID: 31431499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemoprevention for high-risk women: tamoxifen and beyond.
    Fabian CJ; Kimler BF
    Breast J; 2001; 7(5):311-20. PubMed ID: 11906441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics.
    Rubinstein WS
    Fam Cancer; 2008; 7(1):83-9. PubMed ID: 17624601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
    Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
    J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Tseng CW; Wong JB
    JAMA; 2019 Sep; 322(9):857-867. PubMed ID: 31479144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.
    Malone KE; Begg CB; Haile RW; Borg A; Concannon P; Tellhed L; Xue S; Teraoka S; Bernstein L; Capanu M; Reiner AS; Riedel ER; Thomas DC; Mellemkjaer L; Lynch CF; Boice JD; Anton-Culver H; Bernstein JL
    J Clin Oncol; 2010 May; 28(14):2404-10. PubMed ID: 20368571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
    Freedman AN; Yu B; Gail MH; Costantino JP; Graubard BI; Vogel VG; Anderson GL; McCaskill-Stevens W
    J Clin Oncol; 2011 Jun; 29(17):2327-33. PubMed ID: 21537036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.
    Segev Y; Iqbal J; Lubinski J; Gronwald J; Lynch HT; Moller P; Ghadirian P; Rosen B; Tung N; Kim-Sing C; Foulkes WD; Neuhausen SL; Senter L; Singer CF; Karlan B; Ping S; Narod SA;
    Gynecol Oncol; 2013 Jul; 130(1):127-31. PubMed ID: 23562522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis.
    Metcalfe K; Huzarski T; Gronwald J; Kotsopoulos J; Kim R; Moller P; Pal T; Aeilts A; Eisen A; Karlan B; Bordeleau L; Tung N; Olopade O; Zakalik D; Singer CF; Foulkes W; Couch F; Neuhausen SL; Eng C; Sun P; Lubinski J; Narod SA;
    Br J Cancer; 2024 Feb; 130(2):269-274. PubMed ID: 38030749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
    Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
    Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.
    Schrag D; Kuntz KM; Garber JE; Weeks JC
    JAMA; 2000 Feb; 283(5):617-24. PubMed ID: 10665701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations.
    Lubinski J; Kotsopoulos J; Moller P; Pal T; Eisen A; Peck L; Karlan BY; Aeilts A; Eng C; Bordeleau L; Foulkes WD; Tung N; Couch FJ; Fruscio R; Ramon Y Cajal T; Singer CF; Neuhausen SL; Zakalik D; Cybulski C; Gronwald J; Huzarski T; Stempa K; Dungan J; Cullinane C; Olopade OI; Metcalfe K; Sun P; Narod SA;
    JAMA Oncol; 2024 Apr; 10(4):493-499. PubMed ID: 38421676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
    Metcalfe K; Lubinski J; Lynch HT; Ghadirian P; Foulkes WD; Kim-Sing C; Neuhausen S; Tung N; Rosen B; Gronwald J; Ainsworth P; Sweet K; Eisen A; Sun P; Narod SA;
    J Natl Cancer Inst; 2010 Dec; 102(24):1874-8. PubMed ID: 21098759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Graeser MK; Engel C; Rhiem K; Gadzicki D; Bick U; Kast K; Froster UG; Schlehe B; Bechtold A; Arnold N; Preisler-Adams S; Nestle-Kraemling C; Zaino M; Loeffler M; Kiechle M; Meindl A; Varga D; Schmutzler RK
    J Clin Oncol; 2009 Dec; 27(35):5887-92. PubMed ID: 19858402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.
    Cullinane CA; Lubinski J; Neuhausen SL; Ghadirian P; Lynch HT; Isaacs C; Weber B; Moller P; Offit K; Kim-Sing C; Friedman E; Randall S; Pasini B; Ainsworth P; Gershoni-Baruch R; Foulkes WD; Klijn J; Tung N; Rennert G; Olopade O; Couch F; Wagner T; Olsson H; Sun P; Weitzel JN; Narod SA
    Int J Cancer; 2005 Dec; 117(6):988-91. PubMed ID: 15986445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.